BCRX - BioCryst Pharmaceuticals, Inc.
| Previous Close | 4.84 |
| Open | 4.81 |
| Bid | 4.71 x 1000 |
| Ask | 5.21 x 900 |
| Day's Range | 4.81 - 5.03 |
| 52 Week Range | 3.95 - 7.39 |
| Volume | 503,158 |
| Avg. Volume | 1,130,998 |
| Market Cap | 484.156M |
| Beta | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.78 |
| Earnings Date | May 2, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.83 |
- Business Wire•12 days ago
BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger
BioCryst Pharmaceuticals, Inc. and Idera Pharmaceuticals, Inc. today jointly announced that they have each rescheduled their respective Special Meetings of Stockholders to vote on the proposed merger of BioCryst and Idera to July 10, 2018 at 10:00 AM ET.
- PR Newswire•19 days ago
RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger with Idera Pharmaceuticals
BOSTON, April 2, 2018 /PRNewswire/ -- RA Capital Management, LLC ("RA Capital") today announced that it delivered a letter to the Board of Directors of BioCryst Pharmaceuticals, Inc. ("BioCryst") (BCRX) conveying its opposition to BioCryst's proposed merger with Idera Pharmaceuticals, Inc. (IDRA) and its intention to vote against the proposed merger at the upcoming special meeting of stockholders scheduled to be held on May 9, 2018. The full text of the letter is below and will also be included as an exhibit to RA Capital's Schedule 13D to be filed with the SEC.
- Business Wire•20 days ago
BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals
BioCryst Pharmaceuticals, Inc. today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the pending merger of BioCryst and Idera.
- GlobeNewswire•26 days ago
Eyenovia Appoints Three Industry Veterans to Board of Directors
NEW YORK, March 26, 2018-- Eyenovia, Inc., a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics ...
- GlobeNewswire•29 days ago
Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals, Inc. (BCRX)
NEW YORK, March 23, 2018-- Gainey McKenna & Egleston announces that they have filed a class action lawsuit on behalf of their client against BioCryst Pharmaceuticals, Inc. in the United States District ...
- GlobeNewswire•last month
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., March 22, 2018-- BioCryst Pharmaceuticals, Inc., and Idera Pharmaceuticals, Inc., today announced they will be presenting at the 17 th Annual Needham Healthcare ...
- GlobeNewswire•last month
BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., March 15, 2018-- BioCryst Pharmaceuticals, Inc. announced today the dosing of the first patient into APeX-2, a Phase 3 clinical trial evaluating two dosage strengths of BCX7353 ...
- ACCESSWIRE•last month
Blog Exposure - Esperion Therapeutics Reported Positive Top-line Results from First Pivotal Phase-3 Study of its Cholestrol Drug, Bempedoic Acid
Stock Monitor: BioCryst Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 09, 2018 / Active-Investors.com has just released a free research report on Esperion Therapeutics, Inc. (NASDAQ: ESPR ...
- GlobeNewswire•2 months ago
BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2018-- BioCryst Pharmaceuticals, Inc. announced today the dosing of the first patient in APeX-S, a long-term safety trial evaluating two dosage strengths of BCX7353 ...
- GlobeNewswire•2 months ago
BioCryst Reports Fourth Quarter and Full Year 2017 Financial Results
Updates Investors Regarding Proposed Merger with Idera Pharmaceuticals, Inc.. RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2018-- BioCryst Pharmaceuticals, Inc. announced today financial results for the fourth ...
- GlobeNewswire•2 months ago
BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger
Provide Update on Key Benefits of Pending Merger and Comprehensive Evaluation of Strategic Opportunities Leading Up to Definitive Merger Agreement. BioCryst and Idera Boards of Directors Unanimously Recommend ...
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within Healthcare Services Group, Oshkosh, PICO, Chicago Rivet & Machine, Ashland Global, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Healthcare ...
- Zacks•2 months ago
Options Traders Expect Huge Moves in BioCryst (BCRX) Stock
Investors in BioCryst (BCRX) need to pay close attention to the stock based on moves in the options market lately.
- GlobeNewswire•2 months ago
BioCryst to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27
RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2018-- BioCryst Pharmaceuticals, Inc. announced today that its fourth quarter and full year 2017 financial results will be reported on Tuesday, February 27, 2018.. ...
- GlobeNewswire•2 months ago
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., Feb. 19, 2018-- BioCryst Pharmaceuticals, Inc., and Idera Pharmaceuticals, Inc., today announced they will be presenting at two upcoming healthcare-focused ...
- PR Newswire•2 months ago
Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc.
GREENWICH, Conn., Feb. 16, 2018 /PRNewswire/ -- Great Point Partners, LLC ("GPP") today submitted a letter to the Board of Directors of BioCryst Pharmaceuticals, Inc. ("BCRX") expressing its opposition to BCRX's proposed merger with Idera Pharmaceuticals, Inc. The full text of the letter can be found below and is attached as an exhibit to GPP's Schedule 13D, which was filed today and discloses GPP's acquisition of additional BCRX securities.
- Zacks•2 months ago
Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
- Zacks•3 months ago
BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall
Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.
- Motley Fool•3 months ago
BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love
Is this a merger out of weakness and necessity? Wall Street might think so.
- PR Newswire•3 months ago
SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of BioCryst Pharmaceuticals, Inc. - BCRX
NEW YORK , Jan. 22, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...
- MarketWatch•3 months ago
BioCryst and Idera to merge into rare disease company
BioCryst Pharmaceuticals Inc. and Idera Pharmaceuticals Inc. announced early Monday plans to merge into a rare disease company. Shares of both companies were halted in premarket trade. Under the deal, ...
- GlobeNewswire•3 months ago
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases
Filed by BioCryst Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14 a-12 Under the Securities Exchange Act of 1934 Subject Company: Idera ...
- ACCESSWIRE•3 months ago
Today’s Research Reports on Trending Tickers: Acorda Therapeutics and BioCryst Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / January 22, 2018 / U.S. markets rebounded on Friday, posting a weekly gain, as positive earnings outweighed worries of a government shutdown. The Dow Jones Industrial Average ...
